Cybin Inc. announced a registered direct offering of 22,277,750 common shares and pre-funded common share purchase warrants at US$6.51 per share, generating aggregate gross proceeds of US$175,009,911.45. The financing attracted participation from both new and existing institutional investors including Venrock Healthcare Capital Partners, OrbiMed, Point72, Deep Track Capital, and several other prominent healthcare investment firms. Each share or pre-funded warrant includes 0.35 of one common share purchase warrant exercisable at US$8.14 per share with specific trigger conditions.
The capital infusion comes at a critical juncture for Cybin, a late-stage neuropsychiatry company developing next-generation psychedelic treatments for mental health conditions. The company's lead candidate, CYB003, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and is currently in Phase 3 studies for adjunctive treatment of major depressive disorder. The warrant exercise timeline is tied to key clinical milestones, including the release of topline data from the APPROACH trial of CYB003, creating alignment between investor returns and clinical progress.
Cybin's pipeline extends beyond CYB003 to include CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 development for generalized anxiety disorder. The company maintains a broader research pipeline of investigational compounds focused on 5-HT receptors, positioning it as a comprehensive player in the emerging psychedelic therapeutics space. Additional information about Cybin's developments is available at https://ibn.fm/CYBN.
The substantial funding round signals growing institutional confidence in psychedelic medicine's potential to address the substantial unmet needs in mental healthcare. With millions worldwide suffering from treatment-resistant depression and anxiety disorders, Cybin's approach represents a paradigm shift from conventional psychiatric medications. The company's operational presence across Canada, the United States, the United Kingdom, and Ireland underscores its global ambitions for bringing novel mental health treatments to market.
This financing enables Cybin to accelerate its clinical programs while maintaining financial flexibility through strategic warrant structures. The involvement of multiple established healthcare investment firms suggests maturation within the psychedelic sector, moving from speculative venture funding to institutional-grade investment. As mental health continues to represent one of healthcare's most pressing challenges, Cybin's progress could have far-reaching implications for patients, healthcare systems, and the broader acceptance of psychedelic-assisted therapies in mainstream medicine.
